Enesco

Ensysce Biosciences is a clinical-stage pharmaceutical company dedicated to developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose. The company's proprietary technology platforms, Trypsin-Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR), are designed to create 'tamper-proof' prodrugs that only release their active ingredients in the presence of specific digestive enzymes. Its lead product candidate, PF614, is a TAAP-based oxycodone prodrug currently in Phase 3 clinical trials for the treatment of acute and chronic pain. Ensysce is also advancing PF614-MPAR, which received FDA Breakthrough Therapy designation for its ability to prevent overdose by limiting drug release when excessive quantities are ingested. The company aims to provide safer therapeutic options that maintain efficacy while mitigating the risks associated with traditional opioid medications.